Table 2.
Comparison of clinical data before 131I therapy between groups
| Group | 1-6 months | 7-12 months | 13-60 months | >60 months |
|---|---|---|---|---|
| Gender(M/F) | 6/16 | 6/22 | 12/93 | 7/41 |
| Age(y) | 45.50±11.70 | 38.86±11.96 | 44.67±12.64 | 44.77±11.67 |
| FT3(pmol/L) | 21.18±8.86 | 25.05±6.35* | 18.87±9.05* | 22.18±8.38 |
| FT4(pmol/L) | 62.64±37.24 | 64.02±35.42 | 52.18±30.28 | 63.41±37.87 |
| TSH(mIU/L) | 0.06±0.25 | 0.004±0.003# | 0.06±0.36 | 0.01±0.017 |
| TPOAb(IU/mL) | 859.05±575.77 | 899.25±550.87 | 835.48±562.10 | 802.49±574.35 |
| TRAb(IU/L) | 15.76±12.15 | 15.18±12.55 | 16.97±12.11 | 18.48±13.00 |
| 131I dose(mCi) | 8.14±2.32 | 9.59±2.86 | 8.74±3.53 | 7.84±2.86 |
| 24 h maximal 131I uptake rate(%) | 73.89±9.55 | 68.91±10.09 | 72.24±12.92 | 75.85±12.42 |
Data are expressed as mean ± standard deviation according to the distribution.
*p <0.05 represents 7-12 months group versus 13-60 months group
#p <0.05 represents 7-12 months group versus the other three groups